1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
−Removed: As disclosed in the table below, during the third quarter of 2024, certain directors adopted a “Rule 10b5-1 trading arrangement”.
−Removed: These plans provide for the sale of our common stock and are intended to satisfy the affirmative defense in Rule 10b5-1(c).
−Removed: Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (1)
−Removed: Maximum Total Shares of Common Stock to be Sold Under the Plan (2)
−Removed: David Schenkein Director 8/12/2024 2/15/2026 110,524
−Removed: Ryan Watts Chief Executive Officer 9/16/2024 8/1/2025 495,282
−Removed: __________________________________________________
−Removed: (1) In each case, the trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.
−Removed: (2) This amount represents the maximum total shares that could be sold under the plan, but the amounts may change for executive officers due to the sale of shares to satisfy tax withholding requirements.
−Removed: No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the third quarter ended September 30, 2024.
+Added: No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the first quarter ended March 31, 2025.
EXHIBIT INDEX
2 unchanged sentences
Number Filing Date
+Added: Notice of Partial Termination from Genzyme Corporation to the Registrant, dated February 24, 2025
+Added: — — — Filed herewith
+Added: Notice of Partial Termination from Takeda Pharmaceutical Company Limited to the Registrant, dated February 25, 2025
+Added: — — — Filed herewith
+Added: 10.3 Amended O utside D irector C ompensation P olicy
+Added: — — — Filed herewith
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
17 unchanged sentences
— — — Furnished herewith
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, formatted in Inline XBRL (contained in Exhibit 101)
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2025, formatted in Inline XBRL (contained in Exhibit 101)
— — — Furnished herewith
4 unchanged sentences
DENALI THERAPEUTICS INC.
−Removed: November 6, 2024 By:
+Added: May 6, 2025 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 6, 2024 By:
+Added: May 6, 2025 By:
/s/ Alexander O.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.